Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
Peter
P
Sidaway
D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D057240:Patient Preference; D016032:Randomized Controlled Trials as Topic; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate / Q000627:therapeutic use; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014987:Xerostomia / Q000139:chemically induced
D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D013844:Thiazoles; D064804:Urological Agents; D000068737:Tolterodine Tartrate; C520025:mirabegron